Biosensors, Recent Advances in Determination of BDNF and NfL

Mobed, Ahmad; Charsouei, Saeid; Yazdani, Yalda; Gargari, Morad Kohandel; Ahmadalipour, Ali; Sadremousavi, Seyyedeh Reyhaneh; Farrahizadeh, Maryam; Shahbazi, Ali; Haghani, Maryam

doi:10.1007/s10571-023-01401-0

Cited by 9 publications

(4 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Examples include pregnancy tests, diagnosing HIV infection, and quantifying cytokines or soluble receptors in cell supernatant or serum [ 99 ]. In the CSF, brain protein biomarkers can be measured using sandwich ELISA technology [ 100 , 101 ]. However, the sensitivity of ELISA for measuring blood biomarker concentration is not sufficient [ 102 ].…”

Section: Discussion Of Biomarker Detectionsmentioning

confidence: 99%

“…The biological elements such as enzymes, antibodies, and nucleic acids in the bioreceptor interact with the analytes under test, and the transducer converts the biological response into an electrical signal [ 105 ]. Three major transducer-based groups have been developed over the last two decades, allowing different bioreceptors to be applied to different biological targets [ 100 ]. Biosensors, such as nano-bioelectronics, are crucial tools to advance the detection of new specific biomarkers that are molecularly relevant to specific types and stages of human diseases [ 106 , 107 ].…”

Section: Discussion Of Biomarker Detectionsmentioning

confidence: 99%

See 1 more Smart Citation

Tau, Glial Fibrillary Acidic Protein, and Neurofilament Light Chain as Brain Protein Biomarkers in Cerebrospinal Fluid and Blood for Diagnosis of Neurobiological Diseases

Park,

KC,

Paneque

et al. 2024

IJMS

View full text Add to dashboard Cite

Neurological damage is the pathological substrate of permanent disability in various neurodegenerative disorders. Early detection of this damage, including its identification and quantification, is critical to preventing the disease’s progression in the brain. Tau, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL), as brain protein biomarkers, have the potential to improve diagnostic accuracy, disease monitoring, prognostic assessment, and treatment efficacy. These biomarkers are released into the cerebrospinal fluid (CSF) and blood proportionally to the degree of neuron and astrocyte damage in different neurological disorders, including stroke, traumatic brain injury, multiple sclerosis, neurodegenerative dementia, and Parkinson’s disease. Here, we review how Tau, GFAP, and NfL biomarkers are detected in CSF and blood as crucial diagnostic tools, as well as the levels of these biomarkers used for differentiating a range of neurological diseases and monitoring disease progression. We also discuss a biosensor approach that allows for the real-time detection of multiple biomarkers in various neurodegenerative diseases. This combined detection system of brain protein biomarkers holds significant promise for developing more specific and accurate clinical tools that can identify the type and stage of human neurological diseases with greater precision.

show abstract

Section: Discussion Of Biomarker Detectionsmentioning

confidence: 99%

Section: Discussion Of Biomarker Detectionsmentioning

confidence: 99%

Tau, Glial Fibrillary Acidic Protein, and Neurofilament Light Chain as Brain Protein Biomarkers in Cerebrospinal Fluid and Blood for Diagnosis of Neurobiological Diseases

Park,

KC,

Paneque

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…The developed immune device provides a valuable strategy for bioassay and immediate F I G U R E 2 Simple structure of biosensor technology. 33 diagnosis of sepsis, and compared to similar systems, the nanocomposite developed in this study had a simple and low-cost preparation method. 41 PCT was determined with linearity and acceptable LOD using the electrochemical impedance spectroscopy (EIS) technique.…”

Section: De Veloped B I Os En Sor S For De Tec Ti On Of P C Tmentioning

confidence: 99%

Nanobiosensors for procalcitonin (PCT) analysis

Mobed,

Darvishi,

Tahavvori

et al. 2024

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

BackgroundProcalcitonin (PCT) is a critical biomarker that is released in response to bacterial infections and can be used to differentiate the pathogenesis of the infectious process.ObjectiveIn this article, we provide an overview of recent advances in PCT biosensors, highlighting different approaches for biosensor construction, different immobilization methods, advantages and roles of different matrices used, analytical performance, and PCT biosensor construction. Also, we will explain PCT biosensors sensible limits of detection (LOD), linearity, and other analytical characteristics. Future prospects for the development of better PCT biosensor systems are also discussed.MethodsTraditional methods such as capillary electrophoresis, high‐performance liquid chromatography, and mass spectrometry are effective in analyzing PCT in the medical field, but they are complicated, time‐consuming sample preparation, and require expensive equipment and skilled personnel.ResultsIn the past decades, PCT biosensors have emerged as simple, fast, and sensitive tools for PCT analysis in various fields, especially medical fields.ConclusionThese biosensors have the potential to accompany or replace traditional analytical methods by simplifying or reducing sample preparation and making field testing easier and faster, while significantly reducing the cost per analysis.

show abstract

“…To achieve the ideal detection of CNS disorders, particularly AD and PD, there needs to be further deep scientific investigation. It is necessary to understand the exact pathways for each disorder, and multiplex detection is required, not only detecting a single marker for diagnosis [ 318 , 319 ]. Similarly, machine learning and artificial intelligence have been applied to this field to increase the precision of detection [ 320 , 321 ].…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions

Choi,

Chen,

Goldston

et al. 2024

Nano Convergence

View full text Add to dashboard Cite

Central Nervous System (CNS) disorders represent a profound public health challenge that affects millions of people around the world. Diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and traumatic brain injury (TBI) exemplify the complexities and diversities that complicate their early detection and the development of effective treatments. Amid these challenges, the emergence of nanotechnology and extracellular vesicles (EVs) signals a new dawn for treating and diagnosing CNS ailments. EVs are cellularly derived lipid bilayer nanosized particles that are pivotal in intercellular communication within the CNS and have the potential to revolutionize targeted therapeutic delivery and the identification of novel biomarkers. Integrating EVs with nanotechnology amplifies their diagnostic and therapeutic capabilities, opening new avenues for managing CNS diseases. This review focuses on examining the fascinating interplay between EVs and nanotechnology in CNS theranostics. Through highlighting the remarkable advancements and unique methodologies, we aim to offer valuable perspectives on how these approaches can bring about a revolutionary change in disease management. The objective is to harness the distinctive attributes of EVs and nanotechnology to forge personalized, efficient interventions for CNS disorders, thereby providing a beacon of hope for affected individuals. In short, the confluence of EVs and nanotechnology heralds a promising frontier for targeted and impactful treatments against CNS diseases, which continue to pose significant public health challenges. By focusing on personalized and powerful diagnostic and therapeutic methods, we might improve the quality of patients.

show abstract

Biosensors, Recent Advances in Determination of BDNF and NfL

Cited by 9 publications

References 60 publications

Tau, Glial Fibrillary Acidic Protein, and Neurofilament Light Chain as Brain Protein Biomarkers in Cerebrospinal Fluid and Blood for Diagnosis of Neurobiological Diseases

Tau, Glial Fibrillary Acidic Protein, and Neurofilament Light Chain as Brain Protein Biomarkers in Cerebrospinal Fluid and Blood for Diagnosis of Neurobiological Diseases

Nanobiosensors for procalcitonin (PCT) analysis

Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions

Contact Info

Product

Resources

About